Toronto, Canada: Patients authorized to use medical cannabis products experience sustained improvements in their pain, anxiety, depression, and quality of life, according to observational data published in the Canadian Journal of Pain.
Researchers assessed the real-world effectiveness of cannabis products in a cohort of 139 Canadian patients authorized to use medical cannabis. (Nearly 200,000 Canadians are currently registered in Canada’s medical cannabis access program.) Patients’ symptoms were assessed at baseline, 6, 12, and 24 weeks.
Consistent with other long-term observational studies, patients experienced notable improvements in their pain, anxiety, depression, sleep duration, and quality of life. These improvements were maintained throughout the duration of the study. Few, if any, significant adverse events were associated with cannabis treatment.
The study’s authors concluded: “Patients in the study had improved scores with respect to a reduction in pain and pain-related disability, anxiety, depression, sleep, and overall quality of life. Often, the benefits of MC [medical cannabis] were maintained long-term into Week 24. Further data from the … study may offer additional insights into the usage of medical cannabis products and their potential benefits in the general population and inform dosing for future clinical trials focused on cohorts with specific medical conditions or indications.”
According to a recently published meta-analysis of 64 studies, most patients consuming medical cannabis products experience sustained improvements in their health-related quality of life. “Improvements [are] observed across multiple health conditions over short-, medium- and long-term follow-up,” researchers determined.
Full text of the study, “Canadian real-world evidence: Observational 24-week outcomes for health care practitioner authorized cannabis,” appears in the Canadian Journal of Pain.